Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-line Chemotherapy After Cisplatin Plus S-1 or Capecitabine in Metastatic Gastric Cancer

NCT00980603 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT00980603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00980603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-line Chemotherapy After Cisplatin Plus S-1 or Capecitabine in Metastatic Gastric Cancer
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2008
Completion date
May 31, 2011
Enrollment
144 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer